Answers are grounded in this paper and cite their sources.
BACKGROUND: Monoclonal antibodies are the fastest growing class of protein therapeutics. Ligand-binding assays have been the technique of choice for the quantification of these large proteins; however, LC-MS and more recently LC-HRMS have been gaining momentum as robust alternatives for the bioanalysis of antibodies in biological matrices. RESULTS: Optimization of sample preparation and LC-HRMS analysis in MRM(HR) mode has allowed us to develop a highly specific dual-peptide targeted assay for the quantification of Rituximab, in human plasma. The linearity of the assay was established from 1.0 to 200 µg/ml for both light and heavy chain surrogate peptides, with accuracy and precision within 15%. CONCLUSION: LC-HRMS can be an effective tool for the quantification of monoclonal antibodies in regulated bioanalysis.
No takes yet. Share an insight, caveat, or question.
Mekhssian et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: